SUTRO BIOPHARMA, INC.
STRONasdaq
$23.57
↓ -0.7%Jul 17 close · end-of-day
Price
1Y↑ +211.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$308.4M
Enterprise Value
$105.8M
P/E
—
P/S
3.1
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$99.6M
Net Income (TTM)
-$153.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-120.0%
Net Margin
-154.2%
ROE
229.6%
ROIC
—
Debt / Equity
—
Net Cash
$202.6M
Return 1Y
+207.7%
Company profile
Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.
- CEO
- William J. Newell
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 240
- Headquarters
- California
- Website
- sutrobio.com
Management & directors
- Chow Gregory K.CFO
- Chung JaneChief Executive Officer
- Pauling DavidChief Admin. Ofcr. & GC
- Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER
- Leyman BarbaraChief Business Officer
Roles derived from SEC Form 4 filings.
Earnings
STRO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$14.5M↓ -16.5%
Diluted EPS-$2.94↓ -67.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $42.7M | $61.9M | $67.8M | $153.7M | $62.0M | $102.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$71.1M | -$98.5M | -$128.9M | -$89.3M | -$238.5M | -$158.4M |
| Net income | -$32.1M | -$105.5M | -$119.2M | -$106.8M | -$227.5M | -$191.1M |
| Diluted EPS | -$0.99 | -$2.29 | -$2.35 | -$1.78 | -$29.40 | -$22.49 |
| Operating cash flow | -$67.8M | -$81.7M | $3.5M | -$111.6M | -$191.5M | -$177.2M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -166.3% | -159.2% | -190.3% | -58.1% | -384.3% | -154.5% |
| Net margin | -75.2% | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.7M | $8.5M | $14.8M | $17.4M | $63.7M | $9.7M | $11.6M | $14.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$48.7M | -$67.9M | -$65.3M | -$68.5M | -$3.3M | -$48.5M | -$38.0M | -$29.7M |
| Net income | -$48.0M | -$48.8M | -$72.4M | -$76.0M | -$11.5M | -$56.9M | -$46.8M | -$38.5M |
| Diluted EPS | -$0.59 | -$0.59 | -$27.63 | -$9.08 | -$0.14 | -$0.67 | -$12.60 | -$2.94 |
| Operating cash flow | $9.5M | -$64.5M | -$71.7M | -$67.9M | -$44.7M | -$38.2M | -$26.4M | -$42.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -189.4% | -797.2% | -440.7% | -393.8% | -5.2% | -499.9% | -326.7% | -204.2% |
| Net margin | -186.8% | -572.6% | -489.2% | -436.6% | -18.0% | -586.6% | -401.5% | -265.0% |
Company news
May 31, 2026
May 28, 2026
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | Chow Gregory K.· CFO | Option exercise | 2,500 | $0.00 | $0.00 | filing |
| 2026-03-04 | Chung Jane· Chief Executive Officer | Tax withholding | 282 | $21.31 | $6,009.42 | filing |
| 2026-03-04 | Pauling David· Chief Admin. Ofcr. & GC | Tax withholding | 277 | $21.31 | $5,902.87 | filing |
| 2026-03-04 | Chung Jane· Chief Executive Officer | Option exercise | 788 | $0.00 | $0.00 | filing |
| 2026-03-04 | Pauling David· Chief Admin. Ofcr. & GC | Option exercise | 675 | $0.00 | $0.00 | filing |
| 2026-03-02 | Chung Jane· Chief Executive Officer | Tax withholding | 2,779 | $20.55 | $57,108.45 | filing |
| 2026-03-02 | Gerber Hans-Peter· CHIEF SCIENTIFIC OFFICER | Tax withholding | 1,170 | $20.55 | $24,043.50 | filing |
| 2026-03-02 | Pauling David· Chief Admin. Ofcr. & GC | Tax withholding | 970 | $20.55 | $19,933.50 | filing |
| 2026-03-02 | Gerber Hans-Peter· CHIEF SCIENTIFIC OFFICER | Option exercise | 2,843 | $0.00 | $0.00 | filing |
| 2026-03-02 | Chung Jane· Chief Executive Officer | Option exercise | 7,750 | $0.00 | $0.00 | filing |
| 2026-03-02 | Pauling David· Chief Admin. Ofcr. & GC | Option exercise | 2,356 | $0.00 | $0.00 | filing |
| 2026-03-01 | Chung Jane· Chief Executive Officer | Tax withholding | 1,271 | $20.47 | $26,017.37 | filing |
| 2026-03-01 | Pauling David· Chief Admin. Ofcr. & GC | Tax withholding | 551 | $20.47 | $11,278.97 | filing |
| 2026-03-01 | Gerber Hans-Peter· CHIEF SCIENTIFIC OFFICER | Tax withholding | 463 | $20.47 | $9,477.61 | filing |
| 2026-03-01 | Gerber Hans-Peter· CHIEF SCIENTIFIC OFFICER | Option exercise | 1,125 | $0.00 | $0.00 | filing |
| 2026-03-01 | Chung Jane· Chief Executive Officer | Option exercise | 688 | $0.00 | $0.00 | filing |
| 2026-03-01 | Pauling David· Chief Admin. Ofcr. & GC | Option exercise | 842 | $0.00 | $0.00 | filing |
| 2026-03-01 | Chung Jane· Chief Executive Officer | Option exercise | 2,500 | $0.00 | $0.00 | filing |
| 2026-03-01 | Pauling David· Chief Admin. Ofcr. & GC | Option exercise | 500 | $0.00 | $0.00 | filing |
| 2025-12-12 | Chung Jane· Chief Executive Officer | Tax withholding | 894 | $8.02 | $7,165.41 | filing |
| 2025-12-12 | Chung Jane· Chief Executive Officer | Option exercise | 2,500 | $0.00 | $0.00 | filing |
| 2025-10-15 | MATSUI CONNIE | Buy | 50,000 | $0.80 | $39,950.00 | filing |
| 2025-10-15 | Chow Gregory K.· CFO | Buy | 19,750 | $0.81 | $15,997.50 | filing |
| 2025-10-15 | Gerber Hans-Peter· CHIEF SCIENTIFIC OFFICER | Buy | 17,000 | $0.80 | $13,606.80 | filing |
| 2025-10-15 | Chung Jane· Chief Executive Officer | Buy | 12,500 | $0.80 | $10,011.25 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.